RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests a combination of two experimental drugs (M1774 and ZEN-3694) in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to stop cancer cell growth. …
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:47 UTC
-
Supercharged immune cells take on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are trained in a lab to recognize and attack a protein called MUC1 found on cancer cells. The ma…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for recurrent ovarian cancer: triple drug attack launched
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with specific types of recurrent ovarian, fallopian tube, or peritoneal c…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New hope for tough ovarian cancer? drug combo trial begins
Disease control Recruiting nowThis early-phase study tests a new drug (DT2216) combined with standard chemotherapy (paclitaxel) in 30 people with ovarian cancer that has returned and is resistant to platinum-based treatments. The main goal is to find the safest dose of DT2216 when given with paclitaxel, and t…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug combo targets tough ovarian cancer
Disease control Recruiting nowThis early-phase trial tests two drugs, abemaciclib and olaparib, together in people with ovarian cancer that stopped responding to platinum-based chemotherapy. The main goal is to find the safest dose and understand side effects. About 42 participants will take part to see if th…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC